BDRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Biodexa Pharmaceuticals Plc
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 27, 2026
$0.39−0.07 (-14.36%)
Close on Oct 19, 2026
Biodexa Pharmaceuticals Plc revenue by segment
By business segment
| Revenue | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Pipeline R&D [Member] | £578.00K | £343.00K | £674.00K | £1.94M | £989.00K | £1.32M | £873.00K | 100.0% | +68.5% |
| Commercial [Member] | – | – | – | – | £6.65M | £5.60M | £502.00K | – | – |
| Operating income | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | YoY |
|---|---|---|---|---|---|---|---|---|
| Pipeline R&D [Member] | -£7.00M | -£23.04M | -£11.32M | -£11.82M | -£13.28M | -£9.65M | -£9.43M | -69.6% |
| Commercial [Member] | – | – | – | – | -£3.60M | -£20.48M | -£501.00K | – |
| Unallocated amounts [member] | – | – | – | – | – | – | -£2.99M | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Biodexa Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.